<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the Quarterly Period Ended March 31, 1999
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the Transition Period From to
---------------------------------------------------------
Commission File Number 1-11557
PHARMACIA & UPJOHN, INC.
(Exact name of registrant as specified in its charter)
Delaware 98-0155411
(State of incorporation) (I. R. S. Employer
Identification No.)
Pharmacia & Upjohn Company, 95 Corporate Drive, Bridgewater, NJ 08807
(Address of principal executive offices) (Zip Code)
Registrant's telephone number 888/768-5501
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding twelve months, and (2) has been subject
to such filing requirements for the past 90 days. YES X NO
The number of shares of Common Stock, $1 Par Value, outstanding as of May 4,
1999 was 506,757,856.
Page 1 of 22 pages
The exhibit index is set forth on page 18.
1
<PAGE> 2
QUARTERLY REPORT ON FORM 10-Q
PHARMACIA & UPJOHN, INC.
QUARTER ENDED MARCH 31, 1999
INDEX OF INFORMATION INCLUDED IN REPORT
Page
----
PART I - FINANCIAL INFORMATION
Item 1. Financial Statements (Unaudited)
Consolidated Statements of Earnings 3
Condensed Consolidated Statements of Cash Flows 4
Condensed Consolidated Balance Sheets 5
Notes to Consolidated Financial Statements 6
Item 2. Management's Discussion and Analysis of Financial
Condition and Results of Operations 10
Item 3. Quantitative and Qualitative Disclosures About
Market Risk 17
Part II - OTHER INFORMATION
Item 6. Exhibits and Reports on Form 8-K 18
2
<PAGE> 3
PART I - FINANCIAL INFORMATION
Item 1. Financial Statements
PHARMACIA & UPJOHN, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF EARNINGS
For the three months ended March 31
(in millions of U.S. dollars, except per-share data)
<TABLE>
<CAPTION>
Unaudited
---------------------
1999 1998
------- -------
<S> <C> <C>
Net sales $ 1,774 $ 1,586
Cost of products sold 493 486
Research and development 327 277
Selling, general and administrative 668 567
Interest income, net (11) (18)
All other, net (19) (3)
------- -------
Earnings before income taxes 316 277
Provision for income taxes 95 88
------- -------
Net earnings $ 221 $ 189
======= =======
Net earnings per common share:
Basic $ .43 $ .37
======= =======
Diluted $ .42 $ .36
======= =======
</TABLE>
See accompanying notes.
3
<PAGE> 4
PHARMACIA & UPJOHN, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in millions of U.S. dollars)
For the three months ended March 31
<TABLE>
<CAPTION>
Unaudited
-----------------
1999 1998
-------- ------
<S> <C> <C>
Net cash (required) by operations $ (101) $ (57)
-------- ------
Cash flows provided (required) by investment activities:
Proceeds from sale of subsidiaries 35 -
Additions of properties (84) (93)
Purchases of intangibles (36) (1)
Proceeds from sales of investments 100 256
Purchases of investments (30) (161)
Other 6 8
-------- ------
Net cash (required) provided by investment activities (9) 9
-------- ------
Cash flows provided (required) by financing activities:
Repayment of debt (14) (133)
Payments of ESOP debt (22) (16)
Net increase in debt with initial maturity
of 90 days or less 569 392
Dividend payments (141) (141)
Purchases of treasury stock (144) (9)
Proceeds from exercise of stock options 31 6
Other 8 3
-------- ------
Net cash provided by financing activities 287 102
-------- ------
Effect of exchange rate changes on cash (27) (8)
-------- ------
Net change in cash and cash equivalents 150 46
Cash and cash equivalents, beginning of year 857 775
-------- ------
Cash and cash equivalents, end of period $ 1,007 $ 821
======== ======
</TABLE>
See accompanying notes.
4
<PAGE> 5
PHARMACIA & UPJOHN, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(in millions of U.S. dollars)
<TABLE>
<CAPTION>
March 31, December 31,
1999 1998
----------- ------------
ASSETS (unaudited)
<S> <C> <C>
Current assets:
Cash and cash equivalents $ 1,007 $ 857
Short-term investments 268 352
Trade accounts receivable, less allowance
of $102 (1998: $103) 1,412 1,417
Inventories 984 1,032
Other current assets 872 874
-------- --------
Total current assets 4,543 4,532
Long-term investments 435 454
Properties, net 3,135 3,226
Goodwill and other intangible assets, net 1,165 1,238
Other noncurrent assets 853 862
-------- --------
Total assets $ 10,131 $ 10,312
======== ========
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Short-term debt, including current
maturities of long-term debt $ 890 $ 332
Other current liabilities 2,089 2,519
-------- --------
Total current liabilities 2,979 2,851
Long-term debt and guarantee of ESOP debt 479 508
Other noncurrent liabilities 1,294 1,353
-------- --------
Shareholders' equity:
Preferred stock, one cent par value; at
stated value; authorized 100,000,000 shares;
issued 6,823 shares (1998: 6,863 shares) 275 277
Common stock, one cent par value;
authorized 1,500,000,000 shares; issued
508,687,707 shares (1998: 508,682,707 shares) 5 5
Capital in excess of par value 1,351 1,376
Retained earnings 5,573 5,493
ESOP-related accounts (239) (254)
Treasury stock (129) (35)
Accumulated other comprehensive income (1,457) (1,262)
-------- --------
Total shareholders' equity 5,379 5,600
-------- --------
Total liabilities and shareholders' equity $ 10,131 $ 10,312
======== ========
</TABLE>
See accompanying notes.
5
<PAGE> 6
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - UNAUDITED
(ALL U.S. DOLLAR AMOUNTS IN MILLIONS, EXCEPT PER-SHARE DATA)
A - INTERIM CONSOLIDATED FINANCIAL STATEMENTS
The consolidated financial information presented herein is unaudited, other
than the condensed consolidated balance sheet at December 31, 1998, which is
derived from audited financial statements. The interim financial statements and
notes thereto do not include all disclosures required by generally accepted
accounting principles and should be read in conjunction with the financial
statements and notes thereto included in the company's latest annual report on
Form 10-K.
In the opinion of management, the interim financial statements reflect all
adjustments of a normal recurring nature necessary for a fair statement of the
results for interim periods. The current period's results of operations are not
necessarily indicative of results that ultimately may be achieved for the year.
The company is presenting its consolidated statement of earnings in a
"single-step" format and, accordingly, reclassifications of prior year amounts
have been made to conform to this presentation. Certain other reclassifications
of 1998 data have been made to conform to the current year's presentation.
In 1998, the Financial Accounting Standards Board issued Statement of Financial
Accounting Standards (SFAS) No. 133, "Accounting for Derivative Instruments and
Hedging Activities". This statement requires companies to record derivatives on
the balance sheet as assets and liabilities measured at fair value. The
accounting treatment of gains and losses resulting from changes in the value of
derivatives depends on the use of the derivative and whether it qualifies for
hedge accounting. The company expects to adopt SFAS No. 133 no earlier than
January 1, 2000, and is currently assessing the impact of adoption on its
financial position, results of operations, and liquidity.
B - INVENTORIES
<TABLE>
<CAPTION>
March 31, December 31,
1999 1998
---------- -----------
<S> <C> <C>
Estimated replacement cost (FIFO basis):
Pharmaceutical and other finished products $ 512 $ 558
Raw materials, supplies and work-in-process 617 628
---------- -----------
1,129 1,186
Less reduction to LIFO cost (145) (154)
---------- -----------
$ 984 $ 1,032
========== ===========
</TABLE>
Inventories valued on the LIFO method had an estimated replacement cost (FIFO
basis) of $535 at March 31, 1999, and $521 at December 31, 1998.
C - CONTINGENT LIABILITIES
The consolidated balance sheets include accruals for estimated product
litigation and environmental liabilities. The latter includes exposures related
to discontinued operations, including the industrial chemical facility referred
to below and several sites which, under the Comprehensive Environmental
Response, Compensation, and Liability Act, are commonly known as Superfund sites
(see Note D). The company's ultimate liability in connection with Superfund
sites depends on many factors, including the number of other responsible parties
and their financial viability and the remediation methods and technology to be
6
<PAGE> 7
C - CONTINGENT LIABILITIES (continued)
used. Actual costs to be incurred may vary from the estimates given the inherent
uncertainties in evaluating environmental exposures.
With regard to the company's discontinued industrial chemical facility in North
Haven, Connecticut, the company may soon be required to submit a corrective
measures study report to the U.S. Environmental Protection Agency (EPA). As the
corrective action process progresses, it may become appropriate to reevaluate
the existing reserves designated for remediation in light of changing
circumstances. It is reasonably possible that a material increase in accrued
liabilities will be required but it is not possible to determine what, if any,
exposure exists at this time.
D - LITIGATION
The company is involved in a number of legal and environmental proceedings.
These include a substantial number of product liability suits claiming damages
as a result of the use of the company's products and administrative and judicial
proceedings at approximately 50 "Superfund" sites.
While it is not possible to predict or determine the outcome of legal actions
brought against the company, or the ultimate cost of environmental matters, the
company continues to believe that any potentially unaccrued costs and
liabilities associated with such matters will not have a material adverse effect
on the company's consolidated financial position, and unless there is a
significant deviation from the historical pattern of resolution of these issues,
there should not be a material adverse effect on the company's results of
operations or liquidity.
The company has been a party along with a number of other defendants (both
manufacturers and wholesalers) in several federal civil antitrust lawsuits, some
of which were consolidated and transferred to the Federal District Court for the
Northern District of Illinois. These suits, brought by independent pharmacies
and chains, generally allege unlawful conspiracy, price discrimination and price
fixing and, in some cases, unfair competition, and specifically allege that the
company and the other named defendants violated the following: (1) the
Robinson-Patman Act by giving substantial discounts to hospitals, nursing homes,
mail-order pharmacies and health maintenance organizations ("HMOs") without
offering the same discounts to retail drugstores, and (2) Section I of the
Sherman Antitrust Act by entering into illegal vertical combination with other
manufacturers and wholesalers to restrict certain discounts and rebates so they
benefited only favored customers. The Federal District Court for the Northern
District of Illinois certified a national class of retail pharmacies in November
1994. Similar actions by proposed retailer classes have been filed in the state
courts of Alabama, California, Minnesota, Mississippi, and Wisconsin. Eighteen
class action lawsuits seeking damages based on the same alleged conduct have
been filed in 14 states and the District of Columbia. The plaintiffs claim to
represent consumers who purchased prescription drugs in those jurisdictions and
four other states. Two of the lawsuits have been dismissed. The company
announced in 1998 that it reached a settlement with the plaintiffs in the
federal class action cases for $103 which it paid during the first quarter of
1999. The company believes that any potential remaining liability above amounts
accrued will not have a material adverse effect on the company's consolidated
financial position, its results of operations, or liquidity.
E - RESTRUCTURING
The company initiated a global turnaround program in 1997 to rationalize
infrastructure, establish a global headquarters, and eliminate duplicate
resources in manufacturing, administration, and research and development.
At March 31, 1999, the remaining accrual balance was $104.
7
<PAGE> 8
F - COMPREHENSIVE INCOME
Comprehensive income was $27 and $65 for the three months ended March 31, 1999
and March 31, 1998, respectively.
G - EARNINGS PER SHARE
Basic earnings per share is computed by dividing net earnings available to
holders of common stock by the weighted average number of shares of common stock
outstanding. Diluted earnings per share is computed assuming the exercise of
stock options, conversion of preferred stock, and the issuance of stock as
incentive compensation to certain employees. Under these assumptions, the
weighted-average number of common shares outstanding is increased accordingly,
and net earnings is reduced by an incremental contribution to the Employee Stock
Ownership Plan (ESOP). This contribution is the after-tax difference between the
income the ESOP would have received from the preferred stock and the assumed
dividend yield to be earned on the common shares.
The following table reconciles the numerators and denominators of the basic and
diluted earnings per share computations:
<TABLE>
<CAPTION>
For the three months ended March 31, 1999 1999 1998 1998
Basic Diluted Basic Diluted
------- ------- ------- -------
<S> <C> <C> <C> <C>
EPS numerator:
Net earnings $ 221 $ 221 $ 189 $ 189
Less: Preferred stock dividends,
net of tax (3) - (3) -
Less: ESOP contribution, net of tax - (1) - (1)
------- ------- ------- -------
Income available to common shareholders $ 218 $ 220 $ 186 $ 188
======= ======= ======= =======
<CAPTION>
For the three months ended March 31, 1999 1999 1998 1998
Basic Diluted Basic Diluted
------- ------- ------- -------
<S> <C> <C> <C> <C>
EPS denominator:
Average common shares outstanding 507 507 507 507
Effect of dilutive securities:
Stock options - 7 - 3
Convertible preferred stock and
incentive compensation - 10 - 11
------- ------- ------- -------
Total shares 507 524 507 521
======= ======= ======= =======
Earnings per share $ .43 $ .42 $ .37 $ .36
======= ======= ======= =======
</TABLE>
H - SEGMENT INFORMATION
The company's core business is the development, manufacture and sale of
pharmaceutical products. The pharmaceutical segment includes prescription and
nonprescription products for humans and animals. The nonpharmaceutical segment
includes diagnostics, nutrition, plasma and biotechnology products. The
following table shows revenues and expenses for the company's operating segments
and reconciling items necessary to total to amounts in the consolidated
financial statements. Information about segment interest income and expense,
income taxes, corporate support functions, and depreciation are not available on
a segment basis. There are no intersegment revenues.
8
<PAGE> 9
H - SEGMENT INFORMATION (continued)
<TABLE>
<CAPTION>
Sales Profit
------------------ --------------------
For the quarter ended March 31, 1999 1998 1999 1998
------- ------- --------- ---------
<S> <C> <C> <C> <C>
Pharmaceutical $ 1,676 $ 1,430 $ 366 $ 306
Nonpharmaceutical 98 156 24 29
------- ------- --------- ---------
$ 1,774 $ 1,586 390 335
======= =======
Unallocated corporate and other (74) (58)
--------- ---------
Earnings before income taxes $ 316 $ 277
========= =========
</TABLE>
9
<PAGE> 10
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
FINANCIAL REVIEW
OVERVIEW
Sustaining its 1998 turnaround, the company achieved double-digit sales and
earnings growth in the first quarter of 1999. Earnings growth was driven by a 28
percent increase in U.S. pharmaceutical segment sales and improvements in both
the company's gross margin and effective tax rate. In contrast to prior years,
the impact of currency exchange rate fluctuations had a nominal favorable impact
on sales and earnings. In the following discussion of consolidated results, the
three-month period ended March 31, 1999 is compared to the corresponding period
in 1998 unless otherwise noted. The table below provides an overview of
consolidated results in millions of U.S. dollars, except per-share data.
<TABLE>
<CAPTION>
1999 Percent Chg. 1998
------ ------------ ------
<S> <C> <C> <C>
Net sales $1,774 11.8% $1,586
Earnings before income taxes 316 14.1 277
Net earnings 221 17.4 189
Net earnings per common share:
Basic $ .43 16.2 $ .37
Diluted $ .42 16.7 $ .36
</TABLE>
NET SALES
During the last two years, the company sold substantially all of its nutrition
and biotechnology businesses. The following discussion excludes sales of these
divested businesses from total reported sales to facilitate year-to-year
comparisons.
Consolidated sales increased 17 percent in 1999. This growth is composed of a 13
percent volume increase, a 3 percent price increase, and a 1 percent favorable
exchange impact. Sales growth was driven by strong performances of key products
XALATAN and DETROL/DETRUSITOL as both products continue to be launched in new
markets throughout the world. Because the current-to-prior year comparisons in
upcoming quarters will begin to incorporate the 1998 U.S. launch of Detrol,
management does not expect to achieve double-digit sales growth on a
consolidated basis for the full year.
As evidenced in the table below, sales in the U.S. rose 29 percent in the
quarter while sales outside the U.S. increased 9 percent. The proportion of
global sales from the U.S. continues to rise and now represents 41 percent of
total consolidated sales. In Japan, the company's second largest market, sales
increased 22 percent reflecting improved performance and a favorable currency
effect. Sales performance by country in the following table is based on location
of customer and is in millions of U.S. dollars:
10
<PAGE> 11
<TABLE>
<CAPTION>
Net Percent
Percent Change
Three months ended March 31, 1999 Change Excl.Ex.* 1998
------- ------- --------- -------
<S> <C> <C> <C> <C>
United States $ 717 28.6% 28.6% $ 557
Japan 152 22.0 11.1 125
Italy 108 6.4 2.5 102
Germany 91 6.8 2.4 85
United Kingdom 77 13.4 14.0 68
France 74 19.2 14.8 62
Sweden 67 3.9 3.7 64
Spain 43 18.7 14.3 36
Rest of world 415 4.5 7.4 398
------- ------- --------- -------
Total sales, excluding
divested businesses 1,744 16.5 15.6 1,497
Divested businesses 30 n/a n/a 89
------- ------- --------- -------
Consolidated net sales $ 1,774 11.8% 10.9% $ 1,586
======= ======= ========= =======
</TABLE>
*Underlying growth equals percent change excluding currency exchange effects.
The company reports its operations within two segments as illustrated in the
table below:
<TABLE>
<CAPTION>
Percent
Three months ended March 31, 1999 Change 1998
-------- -------- --------
<S> <C> <C> <C>
Pharmaceutical segment sales $ 1,676 17.3% $ 1,430
Nonpharmaceutical segment sales* 68 0.7 67
-------- -------- --------
Total sales, excluding divested businesses $ 1,744 16.5% $ 1,497
======== ======== ========
</TABLE>
*Excludes divested businesses
The increase in pharmaceutical segment sales was driven by a 28 percent increase
in the U.S. Outside the U.S., sales increased 10 percent. Performance of the
nonpharmaceutical segment was flat in the year-to-year comparison. Additional
segment information may be found in Note H to the consolidated financial
statements.
11
<PAGE> 12
PHARMACEUTICAL PRODUCT SALES
A period-to-period consolidated net sales comparison of the company's top 20
pharmaceutical segment products (including generic equivalents where applicable)
is provided in the table below.
<TABLE>
<CAPTION>
U.S. dollars in millions Net
Percent
Three months ended March 31, 1999 Change 1998
------- ------- --------
<S> <C> <C> <C>
GENOTROPIN $ 105 37.0% $ 77
XALATAN 102 45.9 70
CLEOCIN/DALACIN 91 27.6 71
XANAX 88 16.6 76
MEDROL 77 18.5 65
DEPO-PROVERA 66 28.4 51
DETROL/DETRUSITOL 65 n/a 2
CAMPTOSAR 64 52.8 42
NICORETTE 60 15.7 52
FRAGMIN 51 15.6 44
PHARMORUBICIN 46 0.7 46
HEALON 32 (7.3) 34
MICRONASE/GLYNASE 30 (5.1) 31
PROVERA 28 8.2 26
ROGAINE/REGAINE 26 (16.8) 31
AZULFIDINE/SALAZOPYRIN 23 6.5 22
HALCION 22 8.5 20
MIRAPEX/MIRAPEXIN 19 80.8 10
ADRIAMYCIN 18 (0.6) 18
VANTIN 18 (17.1) 21
------- ----- --------
Total $ 1,031 27.4% $ 809
======= ===== ========
</TABLE>
DETROL/DETRUSITOL, a therapy for overactive bladder with symptoms of urinary
urgency, frequency and urge incontinence, led product sales growth in the first
quarter. The product was launched in the U.S. in April 1998 and continues to
experience strong acceptance in the U.S. and international markets. During the
first quarter, the company initiated branded direct-to-consumer television
advertising in the U.S. to continue to build awareness of DETROL for the
treatment of overactive bladder.
XALATAN, a novel therapy for glaucoma, posted double-digit growth in the first
quarter. Sales continue to be led by the U.S. where the product increased its
prescription market share to 25 percent. Non-U.S. sales accounted for 38 percent
of sales in the quarter as the product gained market share and reimbursement in
key European countries. In March, XALATAN was approved in Japan for the
first-line treatment of glaucoma and ocular hypertension and will be launched
during the second quarter. In preparation for the launch in the world's second
largest glaucoma market, the company has tripled its ophthalmology sales force
in Japan.
Sales of GENOTROPIN, a growth hormone, also increased during the first quarter
due in part to the favorable effects of currency and the 1998 retrieval of the
product in Japan from a former licensee. U.S. sales continue to grow as the
company captures an increasing share of new patients.
Other products posting strong sales performances in 1999 included CAMPTOSAR,
NICORETTE, MIRAPEX/MIRAPEXIN, and FRAGMIN. Sales of CAMPTOSAR, for metastatic
colorectal cancer, continued to react positively to the FDA's full approval of
the product in October 1998 based on improved survival data. A portion of the
growth was also attributable to changes in trade inventory buying patterns. The
NICORETTE line of products to treat tobacco dependency performed well due in
part to the recent introduction of the new mint-flavored NICORETTE gum in the
United States. Sales of MIRAPEX/MIRAPEXIN, a treatment for Parkinson's
12
<PAGE> 13
disease, grew over 80 percent as the product maintained its position as the
leading dopamine agonist in both new and total prescriptions in the U.S.
FRAGMIN, a low molecular weight heparin for preventing the formation of blood
clots, registered double-digit growth in 1999. During the quarter, the company
received approval from the FDA for a new indication for FRAGMIN in the U.S. for
the prevention of deep-vein thrombosis following hip replacement surgery.
DEPO-PROVERA, CLEOCIN/DALACIN, MEDROL, XANAX, and PROVERA also recorded higher
sales in 1999. Sales growth of these products was influenced in part by trade
inventory purchasing and is expected to moderate over the remainder of the year.
COSTS, EXPENSES AND OTHER
The company is presenting its consolidated statement of earnings for the first
time in a "single-step" format and, accordingly, reclassifications of prior year
amounts have been made to conform to this presentation. Consolidated expenses,
stated as a percentage of net sales, are provided in the table below.
<TABLE>
<CAPTION>
First quarter ended March 31, 1999 1998
---- ----
<S> <C> <C>
Cost of products sold 27.8% 30.6%
Research and development 18.5 17.5
Selling, general & administrative 37.6 35.7
</TABLE>
A favorable comparison in product and business mix continued to drive cost of
products sold lower as a percentage of sales. Newer products, representing an
increasing percentage of the company's sales, contribute a higher gross margin
than older products in vigorous price competition. The divestment of the
lower-margin nutrition business also contributed to the improvement.
Improvements in production efficiencies in the quarter were offset by
unfavorable manufacturing variances related to increased project activity and
lower volumes.
Both selling, general and administrative (SG&A) expense and research and
development (R&D) expense rose as a percentage of sales in 1999. The increase in
SG&A expense reflected continuing investments in worldwide sales force
expansions and product marketing, particularly for DETROL/DETRUSITOL, EDRONAX,
and XALATAN. R&D expense increased in part due to clinical development spending
on ZYVOX (linezolid), the first of a new class of antibiotics. Management
expects to submit a New Drug Application (NDA) for ZYVOX, now in Phase III
clinical trials, by the end of 1999. In addition, R&D spending on an increased
number of external research collaborations, licensing agreements, and Phase IV
studies drove R&D higher in the current year.
Pharmaceutical segment profits were $366 million in 1999, up from $306 million
in the prior year primarily due to higher U.S. sales levels. Nonpharmaceutical
segment profits fell to $24 million in 1999 from $29 million in 1998, a decline
attributable to the divestment of the majority of the nutrition business.
Net interest income fell in 1999 primarily due to a combination of lower
investment balances and lower interest rates. The increase in "All other, net"
in the current year is attributable to gains on the sale of equity securities
and company holdings in affiliates. The estimated annual effective tax rate
improved from 32 percent in 1998 to 30 percent in 1999 as a result of increased
earnings in jurisdictions with lower tax rates.
TURNAROUND
To rationalize infrastructure, establish a global headquarters, and eliminate
duplicate resources in manufacturing, administration, and research and
development, the company implemented a global turnaround program in 1997. At
March 31, 1999, the remaining accrual balance was $104 million. Cash spending in
the first quarter was primarily for employee separation costs and was
approximately $28 million, down from the first quarter of 1998 when spending
approximated $36 million.
13
<PAGE> 14
The company also incurred restructuring-related charges in 1999 and 1998. These
charges, while not included in restructuring, are one-time costs associated with
the turnaround program. They include relocation expenses to establish the global
headquarters in New Jersey and registration and validation costs associated with
the company's manufacturing rationalization program. Management expects to
record additional restructuring-related expenses, primarily relocation expenses,
in 1999. Relocation costs are expected to range between $55 million and $75
million for the full year and will mainly be incurred during the final three
quarters.
COMPREHENSIVE INCOME
Comprehensive income equals net earnings plus other comprehensive income (OCI).
For Pharmacia & Upjohn, OCI includes currency translation adjustments,
unrealized gains and losses on available-for-sale securities, and minimum
pension liability adjustments. Comprehensive income for the three months ended
March 31, 1999, and March 31, 1998, was $27 million and $65 million,
respectively. The difference between net earnings and comprehensive income in
both years was largely due to unfavorable currency translation adjustments
reflecting the greater strength of the dollar against most major currencies at
March 31 as compared to the previous December 31.
FINANCIAL CONDITION, LIQUIDITY, AND CAPITAL RESOURCES
<TABLE>
<CAPTION>
March 31, December 31,
1999 1998
--------- ------------
<S> <C> <C>
Working capital (U.S. dollars in millions) $ 1,564 $ 1,681
Current ratio 1.53:1 1.59:1
Debt to total capitalization 20.2% 13.0%
</TABLE>
The company's working capital and current ratio decreased at the end of the
first quarter as compared to year-end largely due to an increase in short-term
debt. Higher short-term debt levels also caused the decrease in the percentage
of debt to total capitalization as well as the decrease in net financial assets,
as illustrated below. Significant cash payments in the first quarter, including
expenditures for the stock repurchase program and the settlement of the retail
pharmacy lawsuit, led to the rise in short-term debt levels.
<TABLE>
<CAPTION>
March 31, December 31,
1999 1998
--------- ------------
<S> <C> <C>
Cash, equivalents and investments $ 1,710 $ 1,663
Short-term and long-term debt 1,369 840
--------- ------------
Net financial assets $ 341 $ 823
========= ============
</TABLE>
Net cash required by operations in 1999 increased to $101 million from $57
million for the same period in 1998. The increase in earnings over the prior
year was more than offset by large cash expenditures during the quarter
including the previously mentioned lawsuit settlement payment. Within financing
activities, a significant use of cash in 1999 was the purchase of company stock
under the stock repurchase program announced in late 1998. In both years,
expenditures for the company's quarterly dividend and property, plant, and
equipment (capital) represented material investing uses of cash. Capital
expenditures in 1999 mainly relate to expansion and improvement of the
headquarters in New Jersey and research and manufacturing facilities in Ireland,
Puerto Rico, and Sweden.
The company's future cash provided by operations and borrowing capacity are
expected to cover normal operating cash flow needs, planned capital
14
<PAGE> 15
acquisitions, dividend payments, and stock repurchases as approved by the board
of directors for the foreseeable future.
LITIGATION
Various suits and claims arising in the ordinary course of business, primarily
for personal injury alleged to have been caused by the use of the company's
products, are pending against the company and its subsidiaries. The company also
is involved in several administrative and judicial proceedings relating to
environmental concerns, including actions brought by the U.S. Environmental
Protection Agency (EPA) and state environmental agencies for remedial cleanup at
approximately 50 sites.
Based on information currently available and the company's experience with
lawsuits of the nature of those currently filed or anticipated to be filed which
have resulted from business activities to date, the amounts accrued for product
and environmental liabilities are considered adequate. Although the company
cannot predict and cannot make assurances with respect to the outcome of
individual lawsuits, the ultimate liability should not have a material effect on
its consolidated financial position; and unless there is a significant deviation
from the historical pattern of resolution of such issues, the ultimate liability
should not have a material adverse effect on the company's results of operations
or liquidity.
The company has been a party, along with many other U.S. drug manufacturers and
wholesalers, in numerous related federal and state civil antitrust lawsuits
brought by U.S. independent and chain retail pharmacies and consumers. These
suits claim violations of antitrust and pricing laws as a result of the
defendants providing discounts and rebates to allegedly favored managed care
customers that were not offered to the plaintiffs. Several of the suits are
class actions. The company announced in July that it has reached a settlement
with plaintiffs in the federal class action cases that had been consolidated in
federal court in Chicago, Illinois. The company believes that any potential
remaining liability above amounts accrued will not have a material adverse
effect on the company's consolidated financial position, its results of
operations, or liquidity. Further discussion of current litigation matters is
provided in Note D to the consolidated financial statements.
CONTINGENT LIABILITIES
The company's estimate of the ultimate cost to be incurred in connection with
environmental situations could change due to uncertainties at many sites with
respect to potential cleanup remedies, the estimated cost of cleanup, and the
company's share of a site's cost. With regard to the company's discontinued
industrial chemical facility in North Haven, Connecticut, the company may soon
be required to submit a corrective measures study report to the EPA. As the
corrective action process progresses, it may become appropriate to reevaluate
the existing reserves designated for remediation in light of changing
circumstances. It is reasonably possible that a material increase in accrued
liabilities will be required but it is not possible to determine what, if any,
exposure exists at this time.
YEAR 2000 DATE RECOGNITION PROBLEM
The company's global program to address the year 2000 (Y2K) date recognition
problem continues to make good progress towards its ultimate goal to ensure the
millennium event does not have a material adverse effect on the company's
operations. The project, launched in early 1997 and managed by a global team
consisting of technical, functional and business leaders, is led by a program
director who reports to the chief information officer and an executive
15
<PAGE> 16
operations group. Hundreds of employees worldwide are involved in this effort.
The program encompasses three distinct efforts: (1) assessment and remediation
of information technology (IT) systems; (2) assessment and remediation of
embedded systems; and (3) assessment of high-level business risks and
development of contingency plans to address those risks. Status reports of the
global program's progress have been regularly provided to the company's board of
directors since the inception of the program. Assessment, remediation, and
testing for over 90 percent of IT and embedded systems are expected to be
completed by June 1999; completion of remaining systems is expected during the
third quarter. The latter half of 1999 is reserved for integration testing, a
more comprehensive exercise to ensure critical systems will work together. The
high-level business risk assessment is completed and development of the
resulting contingency plans is well underway, especially for those plans
involving steps to be taken during 1999.
An independent assessment of the program was completed in April 1999. The report
concluded that the company should reach a level of "operational sustainability"
through the year 2000. As defined by the independent assessor, achieving this
level of operational sustainability provides assurance that an organization has
eliminated risk of revenue-interrupting Y2K failures. The company's global
program was assessed as "very good" in comparison to the independent assessor's
best practices model.
Much of the Y2K effort is being supported by a reallocation of existing
resources. The company anticipates total spending of $150 million between 1997
and 2000 largely on replacement of applications that, for reasons other than Y2K
non-compliance, had been previously selected for replacement. Many of the
replacement applications, such as the new SAP financial systems, offer improved
functionality and commonality over predecessor systems and, at the same time,
resolve the Y2K problem. To date, the company estimates actual spending of $115
million of the total projected costs.
There are many factors beyond the company's control that could cause the Y2K
problem to seriously disrupt operations and the company can provide no assurance
that these factors will not cause it to experience business disruptions. For
example, a widespread failure in the utilities industry could severely interrupt
or even halt the company's operations. There are other risks, however, for which
the company may prepare and, in so doing, reduce its exposure. These risks
include a disruption in the supply of product with particular emphasis on
failures of raw material suppliers, third-party manufacturers, and external
distribution channels; internal infrastructure failures such as utilities,
communications, internal IT services and integrated IT systems; non-U.S.
government failures, especially as they impact import and export activity; and
major customer failures or interruptions. The scope of the company's efforts
regarding these risks is limited to key products, key markets, critical
suppliers, and major customers.
To reduce the impact of these failures were they to occur, the company is
developing contingency plans for the most critical business processes. These
plans represent a diversity of approaches and include maintaining higher
inventory levels, developing secondary sources for strategic product chain
links, and documenting back-up procedures and manual work-arounds. The ongoing
assessment of critical external partners also plays an important role in
contingency planning with appropriate actions mapped out at predetermined
decision points depending on the outcome. The company is in the process of
sending questionnaires to all major suppliers, third-party manufacturers, and
customers and auditing critical suppliers and third-party manufacturers in an
attempt to calculate, to the extent possible, where the company faces the
greatest risk of failure. In addition, management will implement a company-wide
program to strictly control and limit changes to major IT systems during the
latter half of 1999 to reduce potential additional exposures and to concentrate
IT resources on integration testing and other Y2K-related efforts. Neither this
program nor the previously mentioned reallocation of resources will have an
adverse effect on non-Y2K mission-critical projects. Barring
16
<PAGE> 17
critical failures arising from factors beyond the company's direct control,
management believes that by meeting the objectives of its Y2K program, the date
recognition problem should not have a material adverse effect on the company's
consolidated financial position, its results of operations, or liquidity.
OTHER
In 1998, the Financial Accounting Standards Board issued Statement of Financial
Accounting Standards (SFAS) No. 133, "Accounting for Derivative Instruments and
Hedging Activities". This statement requires companies to record derivatives on
the balance sheet as assets and liabilities measured at fair value. The
accounting treatment of gains and losses resulting from changes in the value of
derivatives depends on the use of the derivative and whether it qualifies for
hedge accounting. The company expects to adopt SFAS No. 133 no earlier than
January 1, 2000, and is currently assessing the impact of adoption on its
financial position, results of operations, and liquidity.
FORWARD-LOOKING INFORMATION
Certain statements contained in this report, such as statements concerning the
company's anticipated financial or product performance, its ability to pay
dividends, and other non-historical facts, are "forward-looking statements" (as
such term is defined in the Private Securities Litigation Reform Act of 1995).
Since these statements are based on factors that involve risks and
uncertainties, actual results may differ materially from those expressed or
implied by such forward-looking statements. Such factors include, among others:
sales and earnings projections; the effectiveness of and expense estimates
related to future projects including restructuring plans, the Year 2000 date
recognition problem, and conversion to the euro; management's ability to make
further progress under the company's global turnaround program; the company's
ability to successfully market new and existing products in new and existing
markets; the success of the company's research and development activities and
the speed with which regulatory authorizations and product rollouts may be
achieved; fluctuations in currency exchange rates; the effects of the company's
accounting policies and general changes in generally accepted accounting
practices; the company's exposure to product liability lawsuits and
contingencies related to actual or alleged environmental contamination; the
company's exposure to antitrust lawsuits; social, legal and political
developments, especially those relating to health care reform and product
liabilities; general economic and business conditions; the company's ability to
attract and retain current management and other employees of the company; and
other risks and factors detailed in the company's other Securities and Exchange
Commission filings, including its Proxy Statement and Annual Report on Form 10-K
for the year ended December 31, 1998.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
There are no material changes from the disclosures in Form 10-K filed with the
Securities and Exchange Commission on December 31, 1998.
17
<PAGE> 18
PART II - OTHER INFORMATION
Item 6. Exhibits and Reports on Form 8-K.
(a)(i) Exhibit A - Independent Accountant's Report (page 20).
(a)(ii) Exhibit 12 - Ratio of Earnings to Fixed Charges (page 21).
(a)(iii) Exhibit 15 - Awareness of PricewaterhouseCoopers (page 22).
(a)(iv) Exhibit 27 - Financial Data Schedule (EDGAR filing only).
(b) Form 8-K - No reports on Form 8-K were filed during the
quarter ended March 31, 1999.
18
<PAGE> 19
SIGNATURE:
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
PHARMACIA & UPJOHN, INC.
(Registrant)
DATE: May 14, 1999 /S/C.J. Coughlin
C. J. Coughlin
Executive Vice President
and Chief Financial Officer
DATE: May 14, 1999 /S/R.T. Collier
R. T. Collier
Senior Vice President
and General Counsel
19
<PAGE> 20
Exhibit A
Independent Accountant's Report
To the Shareholders and Board of Directors of Pharmacia & Upjohn, Inc.
We have reviewed the condensed consolidated balance sheet of Pharmacia & Upjohn,
Inc. and subsidiaries as of March 31, 1999, and the related consolidated
statements of earnings and condensed consolidated statements of cash flows for
the three-month period ended March 31, 1999 and 1998. These financial statements
are the responsibility of the company's management.
We conducted our review in accordance with standards established by the American
Institute of Certified Public Accountants. A review of interim financial
information consists principally of applying analytical procedures to financial
data and making inquiries of persons responsible for financial and accounting
matters. It is substantially less in scope than an audit conducted in accordance
with generally accepted auditing standards, the objective of which is the
expression of an opinion regarding the financial statements taken as a whole.
Accordingly, we do not express such an opinion.
Based on our review, we are not aware of any material modifications that should
be made to the accompanying financial statements for them to be in conformity
with generally accepted accounting principles.
We previously audited in accordance with generally accepted auditing standards,
the consolidated balance sheet as of December 31, 1998, and the related
consolidated statement of earnings, shareholders' equity, and cash flows for the
year then ended (not presented herein), and in our report dated February 10,
1999 we expressed an unqualified opinion on those consolidated financial
statements. In our opinion, the information set forth in the accompanying
condensed consolidated balance sheet as of December 31, 1998, is fairly stated
in all material respects in relation to the consolidated balance sheet from
which it has been derived.
PricewaterhouseCoopers LLP
Florham Park, New Jersey
April 27, 1999
20
<PAGE> 21
Exhibit Index
-------------
Exhibit No. Description
- ----------- -----------
Exhibit A - Independent Accountant's Report
Exhibit 12 - Ratio of Earnings to Fixed Charges
Exhibit 15 - Awareness of PricewaterhouseCoopers
Exhibit 27 - Financial Data Schedule
<PAGE> 1
EXHIBIT 12
PHARMACIA & UPJOHN, INC. AND SUBSIDIARIES
COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES
(U.S. dollar amounts in millions)
<TABLE>
<CAPTION>
Three Months Year Ended December 31,
Ended
March 31, 1999 1998 1997 1996 1995 1994
-------------- ------ ------ ------ ------ ------
<S> <C> <C> <C> <C> <C> <C>
Earnings from continuing
operations before income taxes $ 316 $1,016 $ 468 $ 838 $1,136 $1,271
Less: Equity in undistributed
net income (loss) of companies
owned less than 50% 5 58 (32) 5 7 8
------ ------ ------ ------ ------ ------
311 958 500 833 1,129 1,263
Add:
Amortization of previously
capitalized interest 3 12 12 11 10 8
Fixed charges included in the above:
Interest and amortization of debt
expense 14 49 58 82 121 139
Rental expense representative
of an interest factor 8 28 38 37 35 35
------ ------ ------ ------ ------ ------
Earnings from continuing operations
before income taxes and fixed
charges $ 336 $1,047 $ 608 $ 963 $1,295 $1,445
====== ====== ====== ====== ====== ======
Interest incurred and amortization
of debt expense $ 18 $ 84 $ 90 $ 115 $ 149 $ 164
Rental expense representative of an
interest factor 8 28 38 37 35 35
------ ------ ------ ------ ------ ------
Total fixed charges $ 26 $ 112 $ 128 $ 152 $ 184 $ 199
====== ====== ====== ====== ====== ======
Ratio of earnings to fixed charges 12.9 9.3 4.8 6.3 7.0 7.2
====== ====== ====== ====== ====== ======
</TABLE>
21
<PAGE> 1
Exhibit 15
Awareness of PricewaterhouseCoopers
May 14, 1999
Securities and Exchange Commission
450 Fifth Street, N.W.
Washington, D.C. 20549
Commissioners:
We are aware that our report dated April 27, 1999 on our review of interim
financial information of Pharmacia & Upjohn (the "Company") as of and for the
period ended March 31, 1999 and included in the Company's quarterly report on
Form 10-Q for the quarter then ended is incorporated by reference in the
Company's Form S-8 Registration Statement (No. 333-74783) dated March 22, 1999,
(No. 333-74785) dated March 22, 1999, (333-76659) dated April 20, 1999, (No.
333-76657) dated April 20, 1999, and (No. 333-03109) dated May 3, 1996.
Very truly yours,
PricewaterhouseCoopers LLP
22
<TABLE> <S> <C>
<ARTICLE> 5
<MULTIPLIER> 1,000,000
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> DEC-31-1999
<PERIOD-END> MAR-31-1999
<CASH> 1,007
<SECURITIES> 0
<RECEIVABLES> 1,514
<ALLOWANCES> 102
<INVENTORY> 984
<CURRENT-ASSETS> 4,543
<PP&E> 5,651
<DEPRECIATION> 2,516
<TOTAL-ASSETS> 10,131
<CURRENT-LIABILITIES> 2,979
<BONDS> 289<F1>
0
275
<COMMON> 5
<OTHER-SE> 5,099
<TOTAL-LIABILITY-AND-EQUITY> 10,131
<SALES> 1,774
<TOTAL-REVENUES> 1,774
<CGS> 493
<TOTAL-COSTS> 493
<OTHER-EXPENSES> 327<F2>
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 6
<INCOME-PRETAX> 316
<INCOME-TAX> 95
<INCOME-CONTINUING> 221
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 221
<EPS-PRIMARY> 0.43
<EPS-DILUTED> 0.42
<FN>
<F1>Does not include guarantee of ESOP debt of $190.
<F2>Only includes R&D expense.
</FN>
</TABLE>
